Over-expression of the potassium channel Kir2.3 using the dopamine-1 receptor promoter selectively inhibits striatal neurons

Neuroscience

Volumn 155, Issue 1, 2008, Pages 114-127

  Falk, T ^a   Xie, J Y ^a   Zhang, S ^a   Kennedy, J ^a   Bennett, J ^a   Yool, A J ^a   Sherman, S J ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

adenovirus; basal ganglia; c Fos; cell culture; gene therapy; inwardly rectifying potassium channel

Indexed keywords

ADENOVIRUS VECTOR; DOPAMINE 1 RECEPTOR; INWARDLY RECTIFYING POTASSIUM CHANNEL; POTASSIUM CHANNEL KIR2.3;

ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; ELECTROPHYSIOLOGY; EMBRYO; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOTOR DYSFUNCTION; MOUSE; NERVE CELL EXCITABILITY; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; STRIATE CORTEX; TISSUE CULTURE; TRANSGENE; VOLTAGE CLAMP;

ALANINE; ANALYSIS OF VARIANCE; ANIMALS; CNIDARIAN VENOMS; CORPUS STRIATUM; EMBRYO, MAMMALIAN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GREEN FLUORESCENT PROTEINS; HUMANS; MEMBRANE POTENTIALS; NEURAL INHIBITION; NEURONS; NEUROTOXINS; PATCH-CLAMP TECHNIQUES; PHOSPHOPYRUVATE HYDRATASE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PREGNANCY; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; TRANSFECTION;

EID: 47249157139     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.04.075     Document Type: Article

References (59)

1. Adams J.R., Troiano A.R., and Calne D.B. Functional imaging in Tourette's syndrome. J Neural Transm 111 (2004) 1495-1506
2. Anderson R.D., Haskell R.E., Xia H., Roessler B.J., and Davidson B.L. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7 (2000) 1034-1038
3. Begany T. First Parkinson's disease gene therapy administered. Neurol Rev 11 10 (2003) 1
4. Chan R.M., Stewart M.J., and Crabb D.W. A direct repeat (DR-1) element in the first exon modulates transcription of the preproenkephalin A gene. Brain Res Mol Brain Res 45 (1997) 50-58
5. Davidson B.L., and Breakefield X.O. Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4 (2003) 353-364
6. Day M., Wang Z., Ding J., An X., Ingham C.A., Shering A.F., Wokosin D., Ilijic E., Sun Z., Sampson A.R., Mugnaini E., Deutch A.Y., Sesack S.R., Arbuthnott G.W., and Surmeier D. Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat Neurosci 9 2 (2006) 251-259
7. Duke G.M., Hoffman M.A., and Palmenberg A.C. Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol 66 3 (1992) 1602-1609
8. + channels overexpressed by adenovirus gene transfer inhibits the excitability of hippocampal neurons. [erratum appears in Proc Natl Acad Sci U S A 1997 94:(17):9511]. Proc Natl Acad Sci U S A 94 (1997) 7070-7075
9. Eltahawy H.A., Feinstein A., Khan F., Saint-Cyr J., Lang A.E., and Lozano A.M. Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. Mov Dis 19 (2004) 969-972
10. Falk T., Zhang S., Erbe E.L., and Sherman S.J. Neurochemical and electrophysiological characteristics of rat striatal neurons in primary culture. J Comp Neurol 494 (2006) 275-289
11. + channels regulates electrical excitability in skeletal muscle. Gene Ther 8 (2001) 1372-1379
12. Falk T., Meyerhof W., Corrette B.J., Schafer J., Bauer C.K., Schwarz J.R., and Richter D. Cloning, functional expression and mRNA distribution of an inwardly rectifying potassium channel protein. FEBS Lett 367 (1995) 127-131
13. Frank M.J. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism. J Cogn Neurosci 17 (2005) 51-72
14. Garcia L., D'Alessandro G., Bioulac B., and Hammond C. High-frequency stimulation in Parkinson's disease: more or less?. Trends Neurosci 28 (2005) 209-216
15. Geldwert D., Norris J.M., Feldman I.G., Schulman J.J., Joyce M.P., and Rayport S. Dopamine presynaptically and heterogeneously modulates nucleus accumbens medium-spiny neuron GABA synapses in vitro. BMC Neurosci 7 (2006) 53-68
16. Gong S., Zheng C., Doughty M.L., Losos K., Didkovsky N., Schambra U.B., Nowak N.J., Joyner A., Leblanc G., Hatten M.E., and Heintz N. A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425 6961 (2003) 917-925
17. Hernandez-Lopez S., Bargas J., Surmeier D., Reyes A., and Galarraga E. D1 receptor activation enhances evoked discharge in neostriatal medium spiny neurons by modulating an L-type Ca conductance. J Neurosci 17 (1997) 3334-3342
18. Holmes A., Lachowicz J.E., and Sibley D.R. Phenotypic analysis of dopamine receptor knockout mice; recent insights into the functional specificity of dopamine receptor subtypes. Neuropharmacology 47 8 (2004) 1117-1134
19. Houeto J.L., Karachi C., Mallet L., Pillon B., Yelnik J., Mesnage V., Welter M.L., Navarro S., Pelissolo A., Damier P., Pidoux B., Dormont D., Cornu P., and Agid Y. Tourette's syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry 76 (2005) 992-995
20. Izhikevich E.M. Solving the distal reward problem through linkage of STDP and dopamine signaling. Cereb Cortex 17 (2007) 2443-2452
21. Joyce M.P., and Rayport S. Mesoaccumbens dopamine neuron synapses reconstructed in vitro are glutamatergic. Neuroscience 99 (2000) 445-456
22. Kaplitt M.G., Feigin A., Tang C., Fitzsimons H.L., Mattis P., Lawlor P.A., Bland R.J., Young D., Strybing K., Eidelberg D., and During M.J. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369 (2007) 2097-2021
23. Kovacs K.J. Invited review c-Fos as a transcription factor: a stressful (re)view from a functional map. Neurochem Int 33 (1998) 287
24. Kuzhikandathil E.V., and Oxford G.S. Dominant-negative mutants identify a role for GIRK channels in D3 dopamine receptor-mediated regulation of spontaneous secretory activity. J Gen Physiol 115 6 (2000) 697-706
25. Lee A.L., Dumas T.C., Tarapore P.E., Webster B.R., Ho D.Y., Kaufer D., and Sapolsky R.M. Potassium channel gene therapy can prevent neuron death resulting from necrotic and apoptotic insults. J Neurochem 86 (2003) 1079-1088
26. Lee S.H., Yajima S., and Mouradian M.M. Neural cell line-specific regulatory DNA cassettes harboring the murine D1A dopamine receptor promoter. Neurosci Res 34 (1999) 225-234
27. Lee S.H., Wang W., Yajima S., Jose P.A., and Mouradian M.M. Tissue-specific promoter usage in the D1A dopamine receptor gene in brain and kidney. DNA Cell Biol 16 (1997) 1267-1275
28. Lee S.P., So C.H., Rashid A.J., Varghese G., Cheng R., Lanca A.J., O'Dowd B.F., and George S.R. Dopamine D1 and D2 receptor co-activation generates a novel phospholipase C-mediated calcium signal. J Biol Chem 279 (2004) 35671-35678
29. Luo J., Kaplitt M.G., Fitzsimons H.L., Zuzga D.S., Liu Y., Oshinsky M.L., and During M.J. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 (2002) 425-429
30. MacKenzie A., Payne C., Boyle S., Clarke A.R., and Quinn J.P. The human preprotachykinin-A gene promoter has been highly conserved and can drive human-like marker gene expression in the adult mouse CNS. Mol Cell Neurosci 16 (2000) 620-630
31. Mallet N., Ballion B., Le Moine C., and Gonon F. Cortical inputs and GABA interneurons imbalance projection neurons in the striatum of parkinsonian rats. J Neurosci 26 14 (2006) 3875-3884
32. McLerie M., and Lopatin A.N. Dominant-negative suppression of I(K1) in the mouse heart leads to altered cardiac excitability. J Mol Cell Cardiol 35 4 (2003) 367-378
33. Metman L.V., and O'Leary S.T. Role of surgery in the treatment of motor complications. Mov Disord 20 Suppl 11 (2005) S45-S56
34. Mink J.W. Basal ganglia dysfunction in Tourette's syndrome: a new hypothesis. Pediatr Neurol 25 (2001) 190-198
35. Monsma Jr. F.J., Brassard D., and Sibley D.R. Identification and characterization of D1 and D2 dopamine receptors in cultured neuroblastoma and retinoblastoma clonal cell lines. Brain Res 492 (1989) 314-324
36. Moro E., Lang A.E., Strafella A.P., Poon Y.Y., Arango P.M., Dagher A., Hutchison W.D., and Lozano A.M. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 56 (2004) 290-294
37. Muramatsu S., Tsukada H., Nakano I., and Ozawa K. Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors. Exp Opin Biol Ther 5 (2005) 663-671
38. Nadeau H., McKinney S., Anderson D.J., and Lester H.A. ROMK1 (Kir1.1) causes apoptosis and chronic silencing of hippocampal neurons. J Neurophysiol 84 (2000) 1062-1075
39. Nicola S., Surmeier J., and Malenka R.C. Dopaminergic modulation of neuronal excitability in the striatum and nucleus accumbens. Annu Rev Neurosci 23 (2000) 185-215
40. Obeso J.A., Rodriguez M.C., and DeLong M.R. Basal ganglia pathophysiology. A critical review. Adv Neurol 74 (1997) 3-18
41. Obeso J.A., Olanow C.W., and Nutt J.G. Basal ganglia, Parkinson's disease and levodopa therapy. Proceedings of a meeting. St Thomas, Virgin Islands, January 2000 (2000)
42. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., and Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann Neurol 47 4 Suppl 1 (2000) S22-S32
43. Perez-Otano I., Mandelzys A., and Morgan J.I. MPTP-Parkinsonism is accompanied by persistent expression of a delta-FosB-like protein in dopaminergic pathways. Brain Res Mol Brain Res 53 (1998) 41-52
44. Perlmutter J.S., and Mink J.W. Deep brain stimulation. Annu Rev Neurosci 29 (2006) 229-257
45. Preisig-Muller R., Schlichthorl G., Goerge T., Heinen S., Bruggemann A., Rajan S., Derst C., Veh R.W., and Daut J. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen's syndrome. Proc Natl Acad Sci U S A 99 (2002) 7774-7779
46. Pruss H., Wenzel M., Eulitz D., Thomzig A., Karschin A., and Veh R.W. Kir2 potassium channels in rat striatum are strategically localized to control basal ganglia function. Brain Res Mol Brain Res 110 (2003) 203-219
47. Qian J., Yehia G., Molina C., Fernandes A., Donnelly R., Anjaria D., Gascon P., and Rameshwar P. Cloning of human preprotachykinin-I promoter and the role of cyclic adenosine 5′-monophosphate response elements in its expression by IL-1 and stem cell factor. J Immunol 166 (2001) 2553-2561
48. Romanelli P., Esposito V., Schaal D.W., and Heit G. Somatotopy in the basal ganglia: experimental and clinical evidence for segregated sensorimotor channels. Brain Res Brain Res Rev 48 (2005) 112-128
49. Schmidtmayer J., Stoye-Herzog M., and Ulbricht W. Rate of action of Anemonia sulcata toxin II on sodium channels in myelinated nerve fibres. Pflugers Arch 394 (1982) 313-319
50. Shen W., Tian X., Day M., Ulrich S., Tkatch T., Nathanson N.M., and Surmeier D.J. Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci 10 11 (2007) 1458-1466
51. Shuen J.A., Chen M., Gloss B., and Calakos N. Drd1a-tdTomato BAC transgenic mice for simultaneous visualization of medium spiny neurons in the direct and indirect pathways of the basal ganglia. J Neurosci 28 11 (2008) 2681-2685
52. Smeding H.M., Speelman J.D., Koning-Haanstra M., Schuurman P.R., Nijssen P., van Laar T., and Schmand B. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology 66 (2006) 1830-1836
53. Starr P. Intrastriatal gene transfer with AAV-neurturin for Parkinson's disease: result of a Phase I trial (2007) Presented at AANS Annual Meeting, April 2007
54. Umegaki H., Chernak J.M., Ikari H., Roth G.S., and Ingram D.K. Rotational behavior produced by adenovirus-mediated gene transfer of dopamine D2 receptor into rat striatum. Neuroreport 8 (1997) 3553-3558
55. White B.H., Osterwalder T.P., Yoon K.S., Joiner W.J., Whim M.D., Kaczmarek L.K., and Keshishian H. Targeted attenuation of electrical activity in Drosophila using a genetically modified K(+) channel. Neuron 31 (2001) 699-711
56. Wickham T.J. Genetic targeting of adenoviral vectors. In: Curiel D.T., and Douglas J.T. (Eds). Vector targeting for therapeutic gene delivery (2002), Wiley-Liss, Inc, Hoboken, NJ 143-170
57. Xue T., Marban E., and Li R.A. Dominant-negative suppression of HCN1- and HCN2-encoded pacemaker currents by an engineered HCN1 construct: insights into structure-function relationships and multimerization. Circ Res 90 12 (2002) 1267-1273
58. Yang Y., Hwang C.K., Junn E., Lee G., and Mouradian M.M. ZIC2 and Sp3 repress Sp1-induced activation of the human D1A dopamine receptor gene. J Biol Chem 275 (2000) 38863-38869
59. Zhou Q.Y., Li C., and Civelli O. Characterization of gene organization and promoter region of the rat dopamine D1 receptor gene. J Neurochem 59 (1992) 1875-1883